SCTC21C
Sponsors
Sinocelltech Ltd.
Conditions
AmyloidosisIgA NephropathyMultiple Myeloma (MM)Relapsed or Refractory Hematologic MalignanciesSystemic Lupus Erythematosus (SLE)
Phase 1
A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies
RecruitingNCT06252298
Start: 2024-02-28End: 2027-02-28Target: 74Updated: 2024-04-22
A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases
Not yet recruitingNCT06774664
Start: 2025-01-31End: 2029-03-31Target: 99Updated: 2025-01-14
A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus
Not yet recruitingNCT07538154
Start: 2026-04-01End: 2028-04-01Target: 159Updated: 2026-04-20
Phase 3
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
RecruitingNCT07297329
Start: 2025-12-29End: 2028-12-01Target: 292Updated: 2026-01-29
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)
RecruitingNCT07388602
Start: 2026-01-08End: 2028-12-01Target: 90Updated: 2026-02-05